Evidence map›Paper›PMID 40181809›Full record

ArticleFrontiers in allergy2025

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a

Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Fausto De Michele and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Luisa BrussinoDipartimento di Scienze Mediche, Università degli Studi di Torino; SCDU Immunologia e Allergologia, AO Ordine Mauriziano Umberto I, Torino, Italy.
Maria AlianiUO Pneumologia e Pneumologia Riabilitativa, ICS Maugeri, IRCCS Bari, Bari, Italy.
Elena AltieriReparto di Pneumologia, P.O. Garbagnate Milanese, Garbagnate Milanese (MI), Italy.
Pietro BraccialeReparto di Pneumologia, Ospedale Ostuni, Ostuni (BR), Italy.
Maria Filomena CaiaffaCattedra e Scuola di Allergologia e Immunologia Clinica, Dipartimento di Scienze Mediche, Università di Foggia, Foggia, Italy.
Paolo CameliRespiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Giorgio Walter CanonicaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
Cristiano CarusoUOSD Allergy and Clinical Immunology, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.
Stefano CentanniRespiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.
Fausto De MicheleUOC Pneumologia e Fisiopatologia Respiratoria, AORN A. Cardarelli, Napoli, Italy.
Stefano Del GiaccoDipartimento di Scienze Mediche e Sanità Pubblica, Università degli Studi di Cagliari, Monserrato, Cagliari, Italy.
Fabiano Di MarcoDepartment of Health Sciences, Università degli Studi di Milano, Pneumologia, ASST Papa Giovanni XXIII, Bergamo, Italy.
Laura MalerbaMedical Affairs R&I, AstraZeneca, Milano, Italy.
Francesco MenzellaPulmonology Unit, Ospedale "S. Valentino", AULSS 2 Marca Trevigiana, Montebelluna (TV), Italy.
Girolamo PelaiaDipartimento di Scienze della Salute, Università Magna Graecia, Catanzaro, Italy.
Paola RoglianiDivision of Respiratory Medicine, University Hospital "Fondazione Policlinico Tor Vergata", Rome, Italy.
Micaela RomagnoliUOC Pneumologia, AULSS 2 Marca Trevigiana, Treviso, Italy.
Pietro SchinoFisiopatologia Respiratoria, Ospedale Generale Regionale, Ente Ecclesiastico "F. Miulli", Acquaviva delle Fonti (BA), Italy.
Jan Walter SchroederAllergy and Clinical Immunology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Gianenrico SennaAllergy Unit and Asthma Center, Verona University Hospital, Verona, Italy.
Alessandra VultaggioDipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Firenze, Italy.
Maria D'AmatoUOSD Malattie Respiratorie "Federico II", Ospedale Monaldi, AO Dei Colli, Napoli, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients present CRSwNP. Methods: This Results: Before benralizumab initiation, CRSwNP patients displayed longer SEA duration, greater oral corticosteroid (OCS) use and blood eosinophil count. After 96 weeks of treatment, the annual exacerbation rate (AER) decreased in both groups, with CRSwNP patients achieving considerable reductions than No-CRSwNP patients (severe AER dropped by 100% and 95.6%, respectively). While lung function improvement was comparable at week 96, CRSwNP patients showed a faster response to benralizumab, with a rise of forced expiratory volume in 1 s (FEV Discussion: These findings show benralizumab long-term effectiveness in SEA patients with and without CRSwNP, highlighting its superior and faster-acting benefits on asthma outcomes in presence of CRSwNP.

Indexed as

asthmabenralizumabCRSwNPeosinophilslong-term

Identifiers

PMID40181809
PMCPMC11965627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.